Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for CDNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -15.50M
March 31, 2026 -2.911M
December 31, 2025 -12.46M
September 30, 2025 -26.48M
June 30, 2025 -53.81M
March 31, 2025 -0.643M
December 31, 2024 -0.903M
September 30, 2024 1.422M
June 30, 2024 -4.85M
March 31, 2024 -1.275M
December 31, 2023 -26.88M
September 30, 2023 -0.025M
June 30, 2023 -1.566M
March 31, 2023 -1.138M
December 31, 2022 -2.372M
September 30, 2022 -1.031M
June 30, 2022 -1.997M
March 31, 2022 0.865M
December 31, 2021 -0.834M
September 30, 2021 -3.133M
June 30, 2021 0.381M
March 31, 2021 189.23M
December 31, 2020 3.964M
September 30, 2020 1.224M
June 30, 2020 158.70M
Date Value
March 31, 2020 -0.735M
December 31, 2019 0.082M
September 30, 2019 0.746M
June 30, 2019 -0.272M
March 31, 2019 -0.688M
December 31, 2018 37.31M
September 30, 2018 10.20M
June 30, 2018 5.076M
March 31, 2018 -2.318M
December 31, 2017 17.92M
September 30, 2017 -9.267M
June 30, 2017 9.595M
March 31, 2017 1.756M
December 31, 2016 -2.134M
September 30, 2016 6.686M
June 30, 2016 20.21M
March 31, 2016 0.165M
December 31, 2015 -0.014M
September 30, 2015 0.479M
June 30, 2015 0.011M
March 31, 2015 3.932M
December 31, 2014 -1.301M
September 30, 2014 35.04M
June 30, 2014 2.703M
March 31, 2014 -0.452M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Natera, Inc. 12.21M
Caris Life Sciences, Inc. -36.90M
Myriad Genetics, Inc. 2.20M
BioRestorative Therapies, Inc. 4.441M
Exagen, Inc. -0.37M